Ascentage Pharma (NASDAQ:
AAPG) will present four preclinical posters at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026.123
The posters feature three drug candidates:
BCR-ABL inhibitor Olverembatinib (HQP1351), FAK/ALK/ROS1 inhibitor APG-2449, and PRC2/EED inhibitor APG-5918.1234
Topics include olverembatinib's efficacy and synergy with chemotherapy in endometrial carcinoma (Abstract 4583), with BTK inhibitor in mantle cell lymphoma (Abstract 5875), APG-2449 enhancing MAPK blockade in BRAF V600E-mutant tumors, and APG-5918 synergizing with topoisomerase I inhibitors in small-cell lung cancer (Abstract 4500).14
None of these three candidates are FDA approved; posters are preclinical.13
Company has approved products in China (Olverembatinib, Lisaftoclax) and ongoing global Phase III trials.24
Sources:
1. https://www.stocktitan.net/news/AAPG/ascentage-pharma-to-present-data-from-four-preclinical-studies-in-7ww9mud8mt27.html
2. https://www.stocktitan.net/sec-filings/AAPG/6-k-ascentage-pharma-group-international-current-report-foreign-issue-668b198e0ead.html
3. https://nationaltoday.com/us/md/rockville/news/2026/03/18/ascentage-pharma-to-present-preclinical-data-at-aacr-2026/
4. https://www.biospace.com/press-releases/ascentage-pharma-to-present-data-from-four-preclinical-studies-in-its-innovative-pipeline-at-american-association-of-cancer-research-aacr-annual-meeting-2026